NMC
ATNM icon

Nine Masts Capital’s Actinium Pharmaceuticals ATNM Stock Holding History

Nine Masts Capital’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35.1K Buy
35,227
+22,287
+172% +$26.5K 0.01% 201
2025
Q4 		$17.6K Buy
+12,940
New +$18.9K ﹤0.01% 115

Other funds holding ATNM

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nine Masts Capital's ATNM Position: Q1 2026 in Review

Nine Masts Capital increased its Actinium Pharmaceuticals (ATNM) stake by 172% in Q1 2026, buying an estimated $26.5K and bringing the position to 35,227 shares worth $35.1K. The position accounts for 0.01% of the portfolio, ranked #201.

Nine Masts Capital first reported a position in ATNM in Q4 2025 and has held it in 2 quarters since. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

  • Nine Masts Capital held 35,227 shares of Actinium Pharmaceuticals worth $35.1K as of Q1 2026.
  • Nine Masts Capital bought 22,287 Actinium Pharmaceuticals shares in Q1 2026, an estimated $26.5K.
  • Actinium Pharmaceuticals made up 0.01% of Nine Masts Capital's portfolio in Q1 2026, its #201 holding.
  • Nine Masts Capital first reported a position in Actinium Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on Nine Masts Capital's 13F filing for Q1 2026, filed 13 May 2026.